Recursion Pharma News Today

Abu Dhabis Mubadala Investment Company plans to expand in Indias healthcare sector, seeking deals in the $200-500 million range. With a focus on pharmaceuticals, outsourced pharma services, and medtech, Mubadala aims to deploy capital meaningfully in India. This move aligns with Mubadalas strategy to generate sustainable financial returns. They have made significant investments globally and are now looking to expand their presence in Indias healthcare landscape.

The AI chip giant, in its first-ever 13F filing with the SEC, also announced small stakes in Recursion Pharmaceuticals (RXRX) and self-driving company…

The closing finished well above its original target and represents one of the largest first-time private life sciences growth funds.

Artificial intelligence is changing life as we know it. These companies are some of the biggest movers and shakers in this brave new world.

Regular and intense aerobic exercise may reduce the risk of colorectal cancer in patients with Lynch Syndrome (LS) by improving the immune system's ability to detect and remove potentially harmful cells, according to researchers at The University of Texas MD Anderson Cancer Center.

Ai4 2023 Attracts Over 2,500 Executives and Technologists From 50+ ...

Ai4 2023 Attracts Over 2,500 Executives and Technologists From 50+ ...

Ai4 2023 Attracts Over 2,500 Executives and Technologists From 50+ Countries

The sizable raise for Genesis comes as the generative AI space race heats up in biomedicine.

Shares of Recursion Pharmaceuticals, Inc. (RXRX) are trading down on Thursday morning after surging to a year-to-date high on yesterday after announcing a collaboration and $50 million investment by Nvidia as a private investment in public equity.